Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema

New England Journal of Medicine

Volumn 348, Issue 21, 2003, Pages 2092-2102

  Ramsey, Scott D ^a   Berry, Kristin ^a   Etzioni, Ruth ^a   Kaplan, Robert M ^b   Sullivan, Sean D ^c   Wood, Douglas E ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; EMPHYSEMA; EXERCISE; HEALTH CARE UTILIZATION; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

COST-BENEFIT ANALYSIS; DRUG THERAPY; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; PNEUMONECTOMY; PULMONARY EMPHYSEMA; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 0037737901     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsa030448     Document Type: Article

References (40)

1. Flaherty KR, Kazerooni EA, Curtis JL, et al. Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 2001;119:1337-46.
2. Geddes D, Davies M, Koyama H, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med 2000;343:239-45.
3. Sciurba FC, Rogers RM, Keenan RJ, et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996;334:1095-9.
4. Gelb AF, McKenna RJ Jr, Brenner M, Schein MJ, Zamel N, Fischel R. Lung function 4 years after lung volume reduction surgery for emphysema. Chest 1999;116:1608-15.
5. Pompeo E, Marino M, Nofroni I, Matteucci G, Mineo TC. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Ann Thorac Surg 2000;70:948-54.
6. Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovasc Surg 1999;118:518-28.
7. Ramsey SD, Sullivan SD, Kaplan RM, Wood DE, Chiang YP, Wagner JL. Economic analysis of lung volume reduction surgery as part of the National Emphysema Treatment Trial. Ann Thorac Surg 2001;71:995-1002.
8. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73.
9. Steele B. Timed walking tests of exercise capacity in chronic cardiopulmonary ill-fliness. J Cardiopulm Rehabil 1996;16:25-33.
10. Kaplan RM, Anderson JP. The General Health Policy Model: an integrated approach. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:309-22.
11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
12. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
13. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984;37:85-95.
14. Orenstein DM, Pattishall EN, Nixon PA, Ross EA, Kaplan RM. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990;98:1081-4.
15. Squier HC, Ries AL, Kaplan RM, et al. Quality of well-being predicts survival in lung transplantation candidates. Am J Respit Crit Care Med 1995;152:2032-6.
16. Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL. Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986;81:565-78.
17. Kaplan RM. Quality of life assessment for cost/utility studies in cancer. Cancer Treat Rev 1993;19:Suppl A:85-96.
18. Physician's desk reference. 56th ed. Montvale, N.J.: Medical Economics, 2002. (Also available at http://www.pdr.net.)
19. SAS version 8. Cary, N.C.: SAS Institute, 2002 (software).
20. Consumer price indexes. Washington, D.C.: Bureau of Labor Statistics, 2003. (Accessed April 29, 2003, at http://www. bls.gov/cpi.)
21. A-A Spectrum Healthcare Products, division of Spectrum Laboratory Products. In: Drug topics red book. Montvale, NJ.: Thomson Medical Economics, 2002.
22. Privately owned vehicle reimbursement rates (POV). Washington, D.C.: General Services Administration, 2003. (Accessed April 29, 2003, at http://www.gsa.gov/Portal/content/policies_content.jsp?contentOID=115105 &contentType=1006&PMTr=1.)
23. Overview of BLS statistics on wages, earnings, and benefits. Washington, D.C.: Bureau of Labor Statistics, 2002. (Accessed April 29, 2003, at http://www.bls.gov/bls/wages.htm.)
24. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075-83.
25. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34.
26. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996;15:1447-58.
27. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002;23:377-401.
28. Holohan TV, Handelsman H. Lung-volume reduction surgery for end-stage chronic obstructive pulmonary disease. Rockville, Md.: Agency for Health Care Policy and Research, September 1996. (AHCPR, publication no. 96-0062.)
29. Drazen JM. Surgery for emphysema not for everyone. N Engl J Med 2001;345:1126-7.
30. Fein AM. Lung volume reduction surgery: answering the crucial questions. Chest 1998;113:Suppl:277S-282S.
31. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
32. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
33. Pliskin JS, Stason WB, Weinstein MC, et al. Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis. Med Decis Making 1981;1:10-28.
34. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation 1982;66:Suppl III:III56-III66.
35. The CEA registry: standardizing the methods and practices of cost-effectiveness analysis. Boston: Harvard Center for Risk Analysis, 2003. (Accessed April 29, 2003, at http://www.hsph.harvard.edu/cearegistry/.)
36. Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung transplantation: a pilot study. Chest 1995;108:1594-601.
37. Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in the Netherlands: a scenario analysis. Chest 1998;113:124-30.
38. van Hout B, Bonsel G, Habbema D, van der Maas P, de Charro F. Heart transplantation in the Netherlands: costs, effects and scenarios. J Health Econ 1993;12:73-93.
39. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness ofimplantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997;126:1-12.
40. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst 1999;91:847-53. [Erratum, J Natl Cancer Inst 2000;92:164-5.]